Skip to main content

Mahoney Michael F's Form 4 filing

Boston Scientific Corp (BSX) · filed Jul 8, 2021

Accession no.
0001225208-21-010501
Filed
Jul 8, 2021
Trade date
May 14-Jul 6, 2021
Filing delay
55 daysLate
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $8.73M. It was filed 55 days after the trade, past the 2-business-day deadline.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mahoney Michael FCIK 0001533022Director, Officer (Chairman, President & CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 14, 2021Common StockGGiftDisposed−34,965$0.00$02,081,822Direct
Jul 6, 2021Common StockMOption exerciseAcquired+134,988$6.28+$847,724.642,216,810Direct
Jul 6, 2021Common StockMOption exerciseAcquired+66,053$7.39+$488,131.672,282,863Direct
Jul 6, 2021Common StockSSaleDisposed−201,041$43.41F2−$8,727,189.812,081,822Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jul 6, 2021Common StockMOption exerciseDisposed−134,988$0.00$0539,953Direct
Jul 6, 2021Common StockMOption exerciseDisposed−66,053$0.00$0594,483Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.28 to $43.79, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)